ubmslateEN-logo-ubm

EN Mobile Logo

Search form

Topics:

SGLT2

SGLT2 Inhibitors 2016: Year-End News Roundup

SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.

© Tetiana Yurchenko/Shutterstock.com

SGLT2

Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?

Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.

Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.

The risk of urinary tract infections (UTIs), but not necessarily genital infections, may vary by agent within the SGLT2 inhibitor class.

Our January list includes new care guidelines for neuropathy, updates to oral medication recommendations, and long-term RYGB outcomes for adolescents.

SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.

SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.

Pages

Subscribe to SGLT2 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.